Black

//Black
  • This medium is designed for the selective isolation of Campylobacter spp., particularly C. jejuni and C. coli , which are major causes of gastrointestinal infection. Campylobacter Blood Free Agar CCDA was formulated to allow replacement of blood with a combination of charcoal, ferrous sulphate, and sodium pyruvate. Selectivity is achieved through the addition of broad spectrum cefoperazone and amphotericin B to inhibit fungi. Inoculated plates are incubated at 41.5°C to improve growth of the thermophilic species including C. jejuni and C. coli. Campylobacter Blood Free Agar CCDA is recommended for food testing in compliance with the requirements of ISO 10272- 1:2017(1) . It can also be used for isolation of Campylobacter spp. from clincal specimens such as faeces(2,3). 1. ISO 10272-1:2017. Microbiology of food and animal feeding stuffs – Horizontal method for detection and enumeration of Campylobacter spp. – Part 1: Detection method. 2. Public Health England. (2014). Investigations of Faecal Specimens for Enteric Pathogens. UK Standards for Microbiology Investigations. B 30 Issue 8.1. 3. Public Health England. (2018). Identification of Campylobacter species. UK Standards for Microbiology Investigations. ID 23 Issue 3.1.
  • Campylobacter Blood Free CCDA Agar One of several media formulations available for the selective isolation of Campylobacter spp., primarily C.jejuni and C.coli, which are the leading cause of enteric illness in the UK. Campylobacter spp. can cause mild to severe diarrhoea, usually self-limiting, but some specific serotypes can trigger acute post-infective conditions affecting the peripheral nervous system, such as Guillain-Barré Syndrome. Campylobacter Blood-Free Selective Medium (CCDA) was first described by Bolton. This medium was formulated to replace blood with a combination of charcoal, ferrous sulphate, and sodium pyruvate. Also, in order to improve selectivity, Cefoperazone replaced the Cephazolin utilised in the original formulation. Bolton recommended incubating inoculated plates at 37°C to improve isolation rates but incubation at 41.5°C is recommended for the isolation of the commonly encountered thermophilic species (C.jejuni & C.coli). Yeast and fungal contaminants can be suppressed with the addition of Amphotericin B. Campylobacter Blood-Free Selective Medium (CCDA) is recommended for food testing. Campylobacter Blood-Free Selective Medium with the addition of Yeast Extract and Cefoperazone is used in the Isolation of Campylobacter species from foodstuffs and swabs in the FDA/BAM Method. The product complies with the requirements of ISO 10272-1:2006.
  • This is a medium intended for the cultivation and isolation of Bordetella pertussis & Haemophilus spp. The base medium contains Charcoal and is enriched with 10% Horse Blood. It can also be used as a maintenance or transport medium for these organisms.
  • Charcoal Agar with 10% Horse Blood & Cephalexin This is one of two media generally used for the selective isolation of Bordetella pertussis. The medium is made selective by the inclusion of Cephalexin, to suppress the unwanted naso-pharyngeal flora often present in specimens submitted for the isolation of Bordetella pertussis, and further enriched with 10% Horse Blood. NB: Although coliforms are inhibited by this medium, Pseudomonas aeruginosa and some fungi will grow.
  • Helicobacter Pylori Medium with 10% Horse Serum, Cefsulodin (10mg/L), Vancomycin (10mg/L) & Amphoteracin (20mg/L) This is a selective medium for the isolation of Helicobacter pylori from clinical samples. The medium is based on a modification of Campylobacter CCDA Blood Free Medium with Charcoal, Ferrous Sulphate and Sodium Pyruvate replacing the Horse Blood and is made selective by the addition of Vancomycin and Cefsulodin to suppress other bacteria and Amphoteracin to inhibit yeasts. 10% Horse Serum is also added to promote optimum growth of helicobacter.
  • Legionella Cystine Free Medium is intended for use in conjunction with Legionella CYE Medium (PP0200) as a secondary diagnostic medium for confirmation of a previously isolated organism. Although it contains Ferric Pyrophosphate and α-ketoglutarate it does not contain any L-Cysteine Hydrochloride. NB : This is a base medium only and will not sustain the growth of Legionella spp.
  • This is a selective medium for the isolation of Legionella spp is used primarily in water and environmental laboratories. The base agar contains Yeast Extract as a source of protein, Charcoal to neutralise growth-inhibiting substances and is supplemented with Ferric Pyrophosphate as a source of iron, L-cysteine hydrochloride and α-ketoglutarate to form amino acid and chelate respectively. ACES buffer is incorporated to maintain the optimal pH for growth. The medium is made selective by the addition of Glycine, Vancomycin & Polymyxin B to inhibit the majority of gram positive and gram negative organisms and Cycloheximide is also included to inhibit yeasts and fungi.
  • This is a selective medium for the isolation of Legionella spp used primarily in clinical and environmental laboratories. The base agar contains Yeast Extract as a source of protein, Charcoal to neutralise growth-inhibiting substances and is supplemented with Ferric Pyrophosphate as a source of iron, L-Cysteine hydrochloride and α-ketoglutarate to form amino acid and chelate respectively. ACES buffer and Potassium hydroxide are incorporated to maintain the optimal pH for growth. The medium is made selective by the addition of Cefamandole and Polymixin to inhibit most gram positive and gram negative organisms and Cyclohexamide is also included to inhibit yeasts and fungi.
  • This is a basic medium for the cultivation of Legionella spp. It is intended primarily for use as a secondary diagnostic medium in conjunction with Legionella Cystine Free Medium (PP0201) for confirmation of a previously isolated organism. NB: This is a basal medium only and although it will sustain the growth of Legionella spp. It contains no selective supplements. It is therefore not recommended as a means of primary isolations from clinical samples.